Radiation ups event-free, not overall survival in ped Hodgkin's

May 31, 2012
Radiation ups event-Free, not overall survival in ped hodgkin's
For children with Hodgkin's lymphoma who respond to chemotherapy, treatment with low-dose involved-field radiation therapy improves event-free survival, but has no significant impact on overall survival, in long-term follow-up, according to a study published online May 29 in the Journal of Clinical Oncology.

(HealthDay) -- For children with Hodgkin's lymphoma who respond to chemotherapy, treatment with low-dose involved-field radiation therapy (IFRT) improves event-free survival (EFS), but has no significant impact on overall survival (OS), in long-term follow-up, according to a study published online May 29 in the Journal of Clinical Oncology.

Suzanne L. Wolden, M.D., from the Memorial Sloan-Kettering Cancer Center in New York City, and colleagues presented long-term follow-up data from the Children's Cancer Group trial of 826 with Hodgkin's lymphoma. Participants were enrolled from 1995 to 1998, and 498 who achieved an initial complete response to were randomly allocated to IFRT or no further treatment. EFS and OS were assessed.

The researchers found that, for the entire cohort, the 10-year EFS and OS rates were 83.5 and 92.5 percent, respectively. For randomly-assigned patients in an as-treated analysis, the 10-year EFS was 91.2 percent for patients treated with IFRT, compared to 82.9 percent for patients with no further therapy (P = 0.004); the 10-year OS was 97.1 percent for IFRT and 95.9 percent for no further therapy (P = 0.50). Risk factors for inferior EFS included bulk disease, "B" symptoms, and nodular sclerosis histology.

"With a median follow-up of 7.7 years, IFRT produced a statistically significant improvement in EFS but no improvement in OS," the authors write. "Patient and disease characteristics and early response assessment will aid in deciding which patients are most likely to benefit from IFRT."

Explore further: High survival with surgery in low-risk neuroblastoma

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

Related Stories

High survival with surgery in low-risk neuroblastoma

April 25, 2012
(HealthDay) -- Surgery alone results in high five-year event-free and overall survival (EFS and OS) rates for patients with low-risk stage 2a and 2b neuroblastoma (NBL), according to research published online April 23 in ...

High-dose melphalan and autologous stem cell transplantation increases survival

October 26, 2011
A team of researchers led by Boston University School of Medicine (BUSM), has found treatment of selected immunoglobulin light chain (AL) amyloidosis patients with high-dose melphalan and autologous stem cell transplantation ...

Adjuvant radiochemotherapy has lasting benefit in gastric cancer

May 18, 2012
(HealthDay) -- Ten-year data from the Southwestern Oncology Group-directed Intergroup Study 0116 confirm the benefits of adjuvant radiochemotherapy after gastric cancer resection in terms of overall survival (OS) and relapse-free ...

New fractionated dosing regimen for anticancer drug significantly improves outcomes for older leukemia patients

April 4, 2012
Using fractionated doses of the targeted anticancer drug gemtuzumab ozogamicin allows for safer delivery of the drug into patients aged 50-70 years with acute myeloid leukaemia (AML) and substantially improves their outcomes. ...

Autologous stem cell transplantation does not improve os in patients with follicular lymphoma

December 21, 2011
High-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT), for previously untreated patients with advanced follicular lymphoma (FL) does not improve overall survival compared with conventional-dose chemotherapy ...

Recommended for you

Study prompts new ideas on cancers' origins

December 16, 2017
Rapidly dividing, yet aberrant stem cells are a major source of cancer. But a new study suggests that mature cells also play a key role in initiating cancer—a finding that could upend the way scientists think about the ...

What does hair loss have to teach us about cancer metastasis?

December 15, 2017
Understanding how cancer cells are able to metastasize—migrate from the primary tumor to distant sites in the body—and developing therapies to inhibit this process are the focus of many laboratories around the country. ...

Cancer immunotherapy may work better in patients with specific genes

December 15, 2017
Cancer cells arise when DNA is mutated, and these cells should be recognized as "foreign" by the immune system. However, cancer cells have found ways to evade detection by the immune system.

Scientists pinpoint gene to blame for poorer survival rate in early-onset breast cancer patients

December 15, 2017
A new study led by scientists at the University of Southampton has found that inherited variation in a particular gene may be to blame for the lower survival rate of patients diagnosed with early-onset breast cancer.

Scientists unlock structure of mTOR, a key cancer cell signaling protein

December 14, 2017
Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed ...

'Bet hedging' explains the efficacy of many combination cancer therapies

December 14, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of "bet hedging," according to a new study published by Harvard Medical School researchers ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.